Takeda Pharmaceutical (TAK) Sales of Property, Plant and Equipment (2018 - 2026)
Powered by 
Analysis
Takeda Pharmaceutical (TAK) Sales of Property, Plant and Equipment (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Sales of Property, Plant and Equipment (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 63.00 Mn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 26.00 Mn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 363.82 Mn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | - |
| 10 | Takeda Pharmaceutical | 2.61 Bn | -3.19 Bn | 5.10 Bn | 6.88 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.88 Mn |
| Mar 31, 2026 | 344,333.70 |
| Dec 31, 2025 | 97,468.51 |
| Jun 30, 2025 | 44.13 Mn |
| Mar 31, 2025 | 209,747.56 |
| Dec 31, 2024 | 52,622.20 |
| Sep 30, 2024 | 194,419.96 |
| Jun 30, 2024 | 57,815.10 |
| Mar 31, 2024 | 13,495.63 |
| Dec 31, 2023 | 1.81 Mn |
| Sep 30, 2023 | 59.55 Mn |
| Jun 30, 2023 | 80,266.13 |
| Dec 31, 2022 | -120,331.42 |
| Sep 30, 2022 | 2.90 Mn |
| Jun 30, 2022 | 262,901.06 |
| Mar 31, 2022 | 12.07 Mn |
| Dec 31, 2021 | 202,336.89 |
| Sep 30, 2021 | 2.82 Mn |
| Jun 30, 2021 | 721,666.44 |
| Mar 31, 2021 | 34.34 Mn |